Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV
- PMID: 21412059
- PMCID: PMC4681576
- DOI: 10.1097/QAD.0b013e3283453fcb
Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV
Abstract
Objective: HIV infection is associated with coagulation abnormalities and significantly increased risk of venous thrombosis. It has been shown that higher plasma levels of coagulation and inflammatory biomarkers predicted mortality in HIV. We investigated the relationship between venous thrombosis and HIV-related characteristics, traditional risk factors of hypercoagulability, and pre-event levels of biomarkers.
Design: A retrospective case-control study of 23 HIV-infected individuals who experienced an incident venous thromboembolic event while enrolled in National Institutes of Health studies from 1995 to 2010 and 69 age-matched and sex-matched HIV-infected individuals without known venous thromboembolism (VTE).
Methods: Biomarkers of inflammation, endothelial dysfunction, coagulation, tissue fibrosis, and cytomegalovirus (CMV) reactivation were assessed by ELISA-based assays and PCR using plasma obtained prior to the event.
Results: VTE events were related to nadir CD4 cell count, lifetime history of multiple opportunistic infections, CMV disease, CMV viremia, immunological AIDS, active infection, and provocation (i.e., recent hospitalization, surgery, or trauma). VTE events were independently associated with increased plasma levels of P-selectin (P = 0.002), D-dimer (P = 0.01), and hyaluronic acid (P = 0.009) in a multivariate analysis. No significant differences in antiretroviral or interleukin-2 exposures, plasma HIV viremia, or other traditional risk factors were observed.
Conclusion: Severe immunodeficiency, active infection, and provocation are associated with venous thromboembolic disease in HIV. Biomarkers of endothelial dysfunction, coagulation, and tissue fibrosis may help identify HIV-infected patients at elevated risk of VTE.
Conflict of interest statement
The authors report no conflicts of interest
Figures

Similar articles
-
HIV disease is associated with increased biomarkers of endothelial dysfunction despite viral suppression on long-term antiretroviral therapy in Botswana.Cardiovasc J Afr. 2018 May/Jun 23;29(3):155-161. doi: 10.5830/CVJA-2018-003. Epub 2018 May 14. Cardiovasc J Afr. 2018. PMID: 29771268 Free PMC article.
-
The effect of initiating combined antiretroviral therapy on endothelial cell activation and coagulation markers in South African HIV-infected individuals.Thromb Haemost. 2010 Dec;104(6):1228-34. doi: 10.1160/TH10-04-0233. Epub 2010 Sep 30. Thromb Haemost. 2010. PMID: 20886182
-
Endothelial activation and cardiometabolic profiles of treated and never-treated HIV infected Africans.Atherosclerosis. 2015 May;240(1):154-60. doi: 10.1016/j.atherosclerosis.2015.03.015. Epub 2015 Mar 14. Atherosclerosis. 2015. PMID: 25795556
-
Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients.Curr Opin HIV AIDS. 2014 Jan;9(1):80-6. doi: 10.1097/COH.0000000000000019. Curr Opin HIV AIDS. 2014. PMID: 24275673 Free PMC article. Review.
-
Inflammatory Biomarkers in the Short-Term Prognosis of Venous Thromboembolism: A Narrative Review.Int J Mol Sci. 2021 Mar 5;22(5):2627. doi: 10.3390/ijms22052627. Int J Mol Sci. 2021. PMID: 33807848 Free PMC article. Review.
Cited by
-
An Inflammatory Story: Antibodies in Tuberculosis Comorbidities.Front Immunol. 2019 Dec 9;10:2846. doi: 10.3389/fimmu.2019.02846. eCollection 2019. Front Immunol. 2019. PMID: 31921122 Free PMC article. Review.
-
Circulating levels of tissue factor microparticle procoagulant activity are reduced with antiretroviral therapy and are associated with persistent inflammation and coagulation activation among HIV-positive patients.J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):367-71. doi: 10.1097/QAI.0b013e3182910121. J Acquir Immune Defic Syndr. 2013. PMID: 23507662 Free PMC article.
-
Associations Between Plasma Immunomodulatory and Inflammatory Mediators With VACS Index Scores Among Older HIV-Infected Adults on Antiretroviral Therapy.Front Immunol. 2020 Jun 30;11:1321. doi: 10.3389/fimmu.2020.01321. eCollection 2020. Front Immunol. 2020. PMID: 32695109 Free PMC article.
-
Cardiovascular Disease and Thrombosis in HIV Infection.Arterioscler Thromb Vasc Biol. 2023 Feb;43(2):175-191. doi: 10.1161/ATVBAHA.122.318232. Epub 2022 Dec 1. Arterioscler Thromb Vasc Biol. 2023. PMID: 36453273 Free PMC article. Review.
-
Soluble Urokinase Plasminogen Activator Receptor Is Predictive of Non-AIDS Events During Antiretroviral Therapy-mediated Viral Suppression.Clin Infect Dis. 2019 Aug 1;69(4):676-686. doi: 10.1093/cid/ciy966. Clin Infect Dis. 2019. PMID: 30418519 Free PMC article.
References
-
- Palella FJ, Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860. - PubMed
-
- Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Walker AS. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet. 2003;362:1267–1274. - PubMed
-
- Smit C, Geskus R, Walker S, Sabin C, Coutinho R, Porter K, et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS. 2006;20:741–749. - PubMed
-
- Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS. 2002;16:1663–1671. - PubMed
-
- Copur AS, Smith PR, Gomez V, Bergman M, Homel P. HIV infection is a risk factor for venous thromboembolism. AIDS Patient Care STDS. 2002;16:205–209. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials